ArticleeNeurologicalSci2025
Weight loss remains a challenge for idiopathic intracranial hypertension patients: A retrospective case series from Kenya.
Article in eNeurologicalSci, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic intracranial hypertension (IIH) is a neurological condition characterized by elevated intracranial CSF pressure without demonstratable evident causes. The mechanisms leading to a particular predilection for women of childbearing age who are overweight and obese or who have recent rapid weight changes remain imprecisely described. If undiagnosed, it can progress to disabling irreversible visual loss. Weight loss is useful in addition to medical therapy in treating the condition. There is a rise of obesity in sub-Saharan Africa (SSA) but there is little published on IIH. Methods: We conducted a retrospective cross-sectional study at our tertiary regional referral neurology centre in Nairobi, Kenya. Data were extracted from medical files of patients meeting the diagnostic criteria for IIH aged >18 years who were diagnosed or managed at AKUHN from January 2011 to December 2022. Results: We identified 152 patients: female-to-male ratio was 9:1, mean age 34.2 years. Mean body mass index (BMI) was 31.2 kgs/m2. Almost a third (32.2 %) had compromised vision at presentation in at least one eye. None had other medical comorbidities to precipitate IIH. H2O. 80.2 % had brain MRI, of which 78.4 % had ancillary IIH findings on imaging. Median cerebrospinal fluid opening pressure was 31 cm. Treatment was acetazolamide alone in 44 %, topiramate alone in 15 %, and combined in 30 %. 9.8 % were referred for neurosurgical evaluation, mainly due to refractory symptoms or intolerance/contraindications to medical therapy. Only 49.3 % had symptom improvement at one year. 52.6 % did not have a formal documented weight loss plan. Mean BMI at one year was 30.9 kg/m Conclusion: Our study describes the first cohort of IIH patients from the East Africa region. Demographics are concordant with those reported internationally. However, our patients failed to lose weight, and emphasizes the need to formally incorporate weight loss plans (diet and exercise) in IIH care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.